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We have xamined the expression of several Duchenne muscular dystrophy (DMD) gene products in amniotic fluid (AF) and chorionic villus 
sampling (CVS) cells. Variable amounts of dystrophin could be detected in most CVS and AF samples by immunoprecipitation followed by Western 
blot analysis. PCR analysis demonstrated the presence of the muscle type dystrophin mRNA in all AF cell cultures. The brain type dystrophin 
mRNA was also detected in some of these cultures. These DMD gene transcripts are of fetal origin and are produced by most or all clonable AF 
cells. The results may facilitate the development of a method for prenatal diagnosis of DMD, based on the expression of the gene in AF and CVS 
cells. 
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1. INTRODUCTION 
Duchenne muscular dystrophy (DMD) is one of the 
most frequent lethal X-linked diseases, characterized by 
progressive degeneration of the muscle. It occurs in 
about l/3,500 newborn males. One-third of the cases are 
due to new mutations. A significant proportion of 
DMD patients also suffer from non-progressive mental 
retardation. Becker muscular dystrophy (BMD) is a 
milder form of X-linked dystrophy with a later onset, 
and is allellic to DMD (reviewed in [l]). The huge gene, 
which is defective in DMD and BMD, spans approxi- 
mately 2,500 kb and is the largest gene known to date. 
The transcription product of the gene in the muscle is 
a 14 kb mRNA, encoding a 427 kDa rod-shaped protein 
dystrophin, which is associated with the sarcolemma 
[2-61. Dystrophin consists of four domains: an N-termi- 
nal actin-binding domain; a domain of spectrin-like re- 
peats; a cysteine-rich domain, which shares homology 
with the Ca*+-binding domain of a-actinin; and a 
C-terminal domain with no similarity to any other 
known protein [2], except for the dystrophin-related 
protein (DRP) encoded by an autosomal gene [7,8]. 
A dystrophin isoform very similar to the muscle type 
dystrophin is present in the brain and is expressed in 
neuronal cells [9,10]. It is regulated by a different pro- 
moter and has a different first exon [l l-141. A third 
dystrophin isoform is expressed in Purkinje cells in the 
brain and is regulated by another promoter [15]. 
We have identified a novel mRNA which is the major 
DMD gene product in many non-muscle tissues, includ- 
*Corresponding author. Fax: (972) (8) 344 125. 
ing neurons and glia cells [l&18]. This mRNA is tran- 
scribed from a small region of the DMD gene. Its pro- 
moter is located in the intron between exons 62 and 63 
of the DMD gene, approximately 150 kb from the 3’ end 
of the gene [17,19]. It shares the 3’ untranslated region 
with dystrophin mRNA and codes for a 70.8 kDa 
polypeptide (Dp71), which contains the C-terminal and 
the cysteine-rich domains of dystrophin (with some 
modifications resulting from alternative splicing), but 
lacks the entire large domain of the spectrin-like repeats 
and the actin-binding N-terminal domain [ 16,19,21,22]. 
The function of Dp71 is unknown, as is the exact func- 
tion of dystrophin. However, the absence of the spec- 
trin-like repeats and the actin-binding domain makes it 
conceivable that the biological role of Dp71 is different 
from that of dystrophin. 
The identification of the DMD gene facilitates the 
development of methods for prenatal diagnosis of the 
disease. About 5565% of DMD cases are caused by 
partial deletions and 5% are due to duplications in the 
gene. Southern blotting, using cDNA probes covering 
the entire mRNA, or PCR (polymerase chain reaction) 
amplification of several exons along the gene, especially 
in the ‘hot-spot’ regions, would facilitate detection of 
these cases [23,24]. For the remaining 30-40% of cases, 
which lack detectable deletion mutations, linkage analy- 
sis by RFLPs (restriction fragment length polymor- 
phisms) and microsatellite DNA segregation is the main 
tool used for carrier detection and prenatal diagnosis 
[25-281. However, in a significant proportion of cases, 
the mutant haplotype can not be identified because of 
non-informativity, small family size and unavailability 
of DNA from deceased probands or other key family 
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members. Furthermore, the high rate (12%) of inter- 
genie recombination events between the polymorphic 
markers used and the site of mutation comprises an- 
other major problem [29]. To date, the only way to 
definitely determine the DMD status of the fetus is to 
obtain fetal muscle by intrauterine biopsy, which is dif- 
ficult to perform and increases the risk of spontaneous 
abortions [30J. It is therefore important to be able to 
directly assay the expression of the gene in cells which 
are easily accessible for prenatal exudation. Such a 
procedure could potentially also be used to detect those 
30% of DMD cases which are due to de novo mutations. 
Amniocytes and chorionic villi are used routinely for 
the diagnosis of a number of genetically determined 
diseases, chromosomal abnormalities and prenatal sex 
determination. Therefore we investigated the expression 
of the DMD gene products in these cells. We show that 
Dp71 and its mRNA are present in both cell types in 
amounts which can be easily detected by Western 
blot analysis and RNase protection assay. The 14 kb 
mRNA of the muscle-type dystrophin is present in small 
amounts which are detectable by PCR. Most impor- 
tantly, low levels of dystrophin could be detected by 
immunoprecipitation followed by Western blot analysis 
in most protein extracts obtained from cultured amni- 
otic fliud (AF) and chorionic villus sampling (CVS) 
cells. 
2. EXPERIMENTAL 
2.1. AF and CVS cell cultures 
Surplus normal or DMD-affected AF and CVS cells, obtained from 
pregnant women for prenatal diagnosis of various genetic traits 
(Ichilov Medical Center), were used for the present investigations. 
AF and CVS cells were taken at the 16th and f+-10th week of 
gestation, respectively. Unless otherwise indicated, the cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple- 
mented with 20% fetal calf serum, 0.02 mM glutamine, 100 x lo3 U/l 
penicillin, 100 mgil streptomycin. The cultures were maintained at 
36.5’C in a humidified CO2 incubator. A human hepatoma cell line 
(HepG2) and HeLa cells were grown in DMEM supplemented with 
15% fetal calf serum. 
2.2. Preparation of RNA 
Total RNA was prepared from cell cultures and tissues by the 
lithium chloride/urea extraction procedure [31]. The integrity of the 
RNA was tested on agaros~fo~~dehyde gels. 
2.3. RNase protection away 
A 266 bp DNA fragment containing 194 bp shared by the dystro- 
phin and Dp71 mRNAs and 72 bp from the specific Dp71 mRNA first 
exon was amplified by reverse transcription (RT)/PCR and cloned in 
the Smal site of the vector Gemini 3 @omega). A cRNA probe was 
synthesized on the linearized plasmid using the Sp6 RNA polymerase. 
The RNase protection assay was performed as described by Melton 
et al. [32] with minor modifications [17]. 
2.4. RTIPCR analysis 
cDNA was synthesized on 10-15 pg total RNA samples using the 
relevant antisense primer and MMLV reverse transcriptase (BRL). 
The cDNA was amplified by PCR using Tag DNA polymerase (USB) 
and suitable primers, as indicated in the legends to the figures. The 
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PCR program included 35 cycles of 1 rain at 94”C, 2 min at 56°C 
(48’C for the brain-type dystrophin mRNA specific primers) and 10 
min at 72°C. In the quantitative PCR only 25 cycles were performed. 
The primers were 20-30 nucleotides long and had 4060% GC content. 
The PCR products were analyzed by Southern blotting, using an 
internal oligonucleotide as the radiolabeled probe. 
2.5. Immunoprecipitation and Western blot analysis 
Protein samples were prepared from AF cell cultures as follows. 
Cultures were washed with PBS and cells were collected using rubber 
policeman in 1 ml/9 cm plate lysis buffer (TNNE + PMSF: 50 mM 
Tris pH 8, 150 nM NaCl, 5 mM EDTA, 1 mM PMSF and 0.4% 
Nonidet-40). After sonication, cell debris was removed by 15 min 
centrifugation (Eppendorf microfuge, maximum speed). The extracts 
were then mixed and shaken with protein A-Sepharose beads for 10 
mins (20 ml/l ml extract). The beads were removed by centrifugation. 
40 fil of protein A-Sepharose resin in 1 ml of TNNE were shaken at 
room temperature for 20 min with 4,ul of rabbit anti-mouse y-globulin 
antibodies. The resin was pelleted and washed with TNNE. The resin 
was then added to 1 ml cell extract samples that were shaken for 2 h 
with 20 ~1 of the antidystrophin monoclonal antibodies (mAb’s) 
MANDRAl or MANDRM. Shaking continued for 18 h. The beads 
were then pelleted, washed, resuspended in 50 ~1 electrophoresis sam- 
ple buffer and boiled for 5 min. The resin was removed by centrifuga- 
tion. All the steps, except where otherwise indicated, were done at 
04°C. 
Western blot analysis was done using 3-10% polyac~lamide/SDS 
gels as previously described by Laemmli [33] and modified by Pons et 
al. [34]. The blots were stained with the mAb, NCL dys 1. Positive 
signals were detected by the ECL system (Amersham). 
2.6. Antibodies 
MANDRAl and MANDRA6 are mAb’s raised against wo differ- 
ent eiptopes in the C-terminal domain of human dystrophin. The two 
Abs do not react with DRP [35]. NCL Dysl is a mAb against an 
epitope in the mid-rod domain of human dystrophm (Novocastra 
Laboratories). 
3. RESULTS 
3.1. Expression of the DMD gene products in amniotic 
JIuid and CVS cells 
RNase protection analysis of total RNA from CVS 
and AF cells, using probes which differentiate between 
the Dp71 and dystrophin mRNAs, revealed substantial 
amounts of Dp71 mRNA in both AF and CVS cells. 
The 194 bp band which is diagnostic for the 14 kb 
mRNA, was not detected in this assay (Fig. 1). Like- 
wise, Western blot analysis using a monoclonal anti- 
body (mAb) directed against an epitope which is com- 
mon to Dp71 and dystrop~n (MANDRAl) detected a 
protein co-migrating with the Dp71 marker but not in 
the region of the dystrophin marker (427 kDa). When 
staining the blot with another mAb, NCL-dysl, which 
is directed against an epitope in the spectrin-like re- 
peats, we observed in some samples a very faint staining 
of a protein co-migrating with dystrophin (Fig. 2). In 
order to increase the sensitivity of the assay we intro- 
duced an immunoprecipitation step which allowed us to 
load immunoreactive proteins derived from approxi- 
mately 50-fold more cell extract in each slot. The intro- 
duction of the i~~opr~ipitation step before the 
Western blot analysis also made it possible to increase 
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Fig. 1. RNase protection analysis of Dp71 and dystrophin mRNAs 
in AF and CVS cell cultures. Assays were performed on 15 pug total 
RNA samples. The 266 and 194 nucleotide protected fragments are 
diagnostic for Dp71 and dystrophin mRNAs, respectively. The human 
muscle RNA was prepared from either muscle tissue (T) or from 
differentiated muscle cell cultures (T.C.) 
the specificity of the assay by using a different anti- 
dystrophin antibody in each step. Indeed, when the im- 
munoprecipitation was performed with MANDRAl 
and the blot was stained with NCL-dysl, a band co- 
migrating with dystrophin could be clearly detected in 
seven of nine different normal AF cell samples (Fig. 
2A). Such a band was not detected in extracts from AF 
cells derived from a DMD-affected fetus (Fig. 2A). In 
all the extracts of CVS cultures that were tested, which 
were derived from six different normal fetuses, a band 
co-migrating with dystrophin was detected after im- 
munoprecipitation. No such band was detected in ex- 
tracts of the two samples of CVS from DMD-affected 
fetuses. In general, the signal produced with the extracts 
from CVS cells was weaker than that obtained from AF 
cells (Fig. 2B). Similar results were obtained when using 
a mAb directed against a different epitope in the 
C-terminal domain of dystrophin, MANDRA6, for the 
immunoprecipitation (data not shown). 
These results indicate that small and variable 
amounts of dystrophin are present in most AF and CVS 
cell samples. To further analyze the expression of the 
DMD gene transcripts in AF and CVS cells, we em- 
ployed the very sensitive PCR method for the detection 
of dystrophin mRNA. Several combinations of primers 
were used for the synthesis of cDNA and PCR amplifi- 
cation (Fig. 3A). One group of primers was from the 
region of divergence of the sequences of the Dp71 and 
dystrophin mRNAs. These primers were designed to 
differentiate between sequences pecific to the dystro- 
phin mRNAs and sequences pecific for the mRNA 
encoding Dp71 (primers 1, 2 and 2L). Another combi- 
nation of primers was designed to amplify sequences in 
the region encoding the N-terminal (actin-bin~ng) do- 
main common to the muscle- and brain-type dystrophin 
mRNAs and the recently discovered Purkinje cell 
dystrophin, but absent in Dp71 mRNA (primers 3, 4 
and 5; results not shown). A third group of primers 
from the 5’ end of the 14 kb mRNAs was designed to 
differentiate between the muscle and brain-type dystro- 
phin mRNAs (Primers 7, 8M and 8B). RNA samples 
from cultures of AF cells of 13 fetuses and CVS cells of 
6 fetuses were analyzed. As expected from the RNase 
protection assay, primers diagnostic for Dp71 mRNA 
produced a strong signal with all the cDNA prepara- 
tions (Fig. 3B). In addition, all cDNA preparations de- 
rived from AF cells produced signals with primers diag- 
nostic for sequences common to the muscle and brain 
dystrophin 14 kb mRNAs and lacking the Dp71 mRNA 
(Fig. 3C). It should be pointed out that these sets of 
primers cannot differentiate between Dp71 and Apo 
dystrophin 3 mRNAs, and between dystrophin and 
Dpl16 mRNAs. Apo dys 3 and Dpl16 were recently 
Fig. 2. Immuaoprecipitation and Western blot analysis of dystrophin 
from (A) AF cell cultures (AF) or (B) CVS cell cultures (CVS). Prep- 
aration of cell extracts, immunoporeeipitation and Western blot anal- 
ysis are described in section. 20 ~1 of immunoprecipitated protein 
samples, equivalent o 40% of one confluent 9 cm Petri dish were 
loaded on the gel. In the untreated sample approximately 4Opg protein 
were analyzed (equivalent of approximately 2% of the protein ex- 
tracted from one plate). The muscle control samples contained 25 pg 
protein. AF 1511 = extract of an AF cell culture derived from a single 
clone of a male fetus. AF*l and CVS are cuitures of cells obtained 
from DMD-cited donors. 
22.5 
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described [36,37]. However, the sets of primers de- 
scribed below are specific for dystrophin mRNAs. 
A band diagnostic for the muscle-TV-specific tirst 
exon was detected with all the AF cDNA samples (Fig. 
3D). The variability in the strength of the signals pro- 
duced with various RNA preparations was greater than 
that obtained with primers complementary to sequences 
in the common region. The results with the cDNA pre- 
A 
pared from RNA extracted from CVS cells were similar 
to those obtained with the AF cell preparations, but 
were less consistent, and with some RNA samples the 
band diagnostic for the 14 kb mRNAs was not detected. 
Sequences pecific for the brain-type dystrophin mRNA 
were only detected in a few RNA samples using the 
same AF and CVS RNA extracts and PCR conditions 
(Fig. 3E). 
Dp71 
‘,.:.“. 
AF 1, 
/ ;I, _( 
_: AF12 
AF13 
NO EDNA 
No RNA 
Fig. 3. PCR analysis of dystrophin and Dp71 mRNAs in AF and CVS cells. (A) Schematic presentation of the primers used for cDNA synthesis 
and PCR. Open bars, coding sequences pecific to dystrophin mRNA; slanted, striped bars, coding sequences common to dystrophin and Dp71 
mRNAs; dotted and horizontally striped bars, first and specific exons of muscle and brain dystrophin mRNA, respectively; black bar, first and 
specific exon of Dp71 mRNA. The arrows under the bar show the position of the antisense primers used for cDNA synthesis (1,3,6) and PCR 
fl,4,7). Arrows above the bars indicate the position of the sense primers used in the PCR ampl~~tion (2,2L, 5,8M, 8B). (B) PCR ~pli~~tion 
of Dp71 mRNA. Primer 1 was used for cDNA synthesis. Primers 1 and 2L were used for PCR. (C) PCR amplification of dystrophin mRNA. Primer 
1 was used for cDNA synthesis and primers 1 and 2 for PCR. (These primers will also amplifyDpll6 mRNA if present; [371.) (D) PCR amplification 
of muscle-type dystrophin mRNA. Primer 7 was used for cDNA synthesis and primers 7 and 8M for PCR amplification. (E) PCR amplification 
of brain-type dystrophin mRNA. The cDNA described in D was amplified with primers 7 and 8B. The PCR products were analyzed by Southern 
blotting using suitable internal oligonucleotide probes. The no RNA and no cDNA controls were intended to detect contamination introduced 
during RT/PCR. HepCZ, rat muscle and rat brain RNAs were used as positive controls for Dp71, muscle- and brain-type dystrophin mRNAs, 
respectively. Similar results were obtained when nested PCR was performed using different primers for the cDNA synthesis in PCR amplifi~tion 
(e.g. primers 6, 7, 8M). 
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Using the same primers and PCR conditions, we did 
not detect dystrophin sequences in human hepatoma 
RNA (HepGZ) and HeLa cell RNA. 
3.2. Origin of the cells expressing the dystrophin mRNA 
sequence 
In view of the extreme sensitivity of the PCR and the 
variability in the intensity of the signal, we addressed 
the possibility that the 14 kb mRNA sequences detected 
by PCR in AF and CVS cells could be due to the con- 
tamination of the biopsies with cells of maternal origin 
(e.g. smooth muscle). To test this possibility we exam- 
ined the expression of the DMD gene in AF cells ob- 
tained from the biopsy of an affected fetus which has a 
deletion spanning exon 7-34 of the DMD gene. RNA 
from AF cells of this fetus and from AF cells of normal 
fetuses were analyzed by RT/PCR, using two sets of 
primers, which are described in Fig. 4A. cDNA was 
synthesized using either primer A or primer C. Primers 
B and D were expected to amplify cDNA of the mutated 
dystrophin mRNA only (of fetal origin), and primers C 
and D of normal dystrophin mRNA only (of maternal 
origin). The first set of primers (B,D) amplified only 
cDNA which was synthesized with an RNA template 
derived from the AF cells from the affected fetus. No 
fragment diagnostic for maternal dystrophin mRNA 
was obtained using the same cDNA and the second set 
of primers (Fig. 4B). On the other hand, when we used 
RNA from normal AF cells as a template for the 
cDNA, no band was obtained with the primers diagnos- 
tic for the deleted gene product (due to the great dis- 
tance between the locations of the complementary se- 
quences in normal dystrophin mRNA). However, a 
strong band was obtained with the primers diagnostic 
for the normal dystrophin mRNA. Thus, in the AF cells 
of the DMD-affected embryo, only transcripts derived 
from the deleted DMD gene were detected and they 
contained the sequence of the muscle-type dystrophin 
mRNA. 
The DMD-affected embryo expressed normal 
amounts of Dp71 (not shown). This result is expected 
since the promoter of Dp71 is located between exons 62 
and 63, i.e. 3’ to the deleted region of the DMD gene 
and is therefore unaffected by the deletion. 
3.3. Expression of dystrophin sequences i not con$ned 
to a small subset of AF cells 
In order to obtain further insight into the cellular 
origin of the low levels of dystrophin mRNA in AF 
cultures we attempted to test whether the transcript is 
produced by a small fraction of the AF cell population. 
Cultures of AF cells, derived from one male and one 
female fetus, were plated in cloning densities on a feeder 
layer. Ten days following plating, single well-isolated 
colonies of cells were marked, transferred separately to 
new plates, and amplified to mass culture. The cultures 
were harvested, RNA was extracted, and cDNA pre- 
pared and subjected to PCR analysis using three sets of 
primers described in Fig. 3A (primers 1 and 2, primers 
6 (cDNA), 7 and 8M (PCR) and primers 6 (cDNA), 7 
and 8B (PCR)). The muscle-type dystrophin mRNA 
sequence was detected in all RNA preparations (not 
shown). 
Interestingly, while in all four clones derived from 
one AF sample no brain-type dystrophin mRNA was 
detected, all six clones derived from the other AF sam- 
ple were positive for the brain-type dystrophin mRNA 
(not shown). 
These results suggest that muscle-type dystrophin 
mRNA is produced by most or all of the clonable AF 
cells and is not limited to a small subset of the cell 
population. Growing the cells in nutritional medium 
which enhances the differentiation of myoblasts into 
muscle fibers (2HI medium) did not result in noticeable 
morphological differentiation and did not affect the 
PCR results. 
Since one of the two donor fetuses used in this exper- 
iment was a male, we could also check whether the 
cloned cells were of fetal or maternal origin, by testing 
their karyotype. The analysis showed that all four 
cloned cell populations which we examined had an XY 
karyotype. Immunoprecipitation followed by Western 
blot analysis of protein extracts of one of these clones 
(AFI.50) demonstrated the presence of dystrophin in 
these cells (Fig. 2A). These results corroborate the con- 
clusion derived from the PCR analysis of the AF cells 
of an embryo harboring a deletion in the DMD gene, 
that the dystrophin is expressed in cells which originated 
from the fetus and not from the mother. 
3.4. The relative abundance of dystrophin mRiVA in AF 
cells 
To obtain a rough estimation of the amounts of 
dystrophin mRNA in the AF cells, we performed a 
quantitative PCR analysis of RNA from several sam- 
ples of AF cells, HepG2 and HeLa cells and several 
dilutions of cDNA prepared from muscle RNA. cDNA 
was prepared with primer 6 (Fig. 3A), and a pair of 
primers diagnostic for muscle dystrophin (8M and 7) 
were used for PCR (Fig. 5). The results indicate that the 
amounts of muscle dystrophin mRNA in the AF cells 
is between l/10 and l/100 of the amount of dystrophin 
mRNA in the muscle. Under the same conditions, no 
dystrophin mRNA was detected in HepG2 and HeLa 
cells. At the protein level, a rough estimation based on 
Western blot analysis suggests that the amount of 
dystrophin in AF and CVS cells is less than 1% of that 
in muscle. 
4. DISCUSSION 
It was previously shown that Dp71 is expressed in 
many non-muscle cell types, including very early em- 
bryos. Therefore, its detection in AF and CVS cells in 
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Fig. 4. PCR analysis of dystrophin mRNA from AF cells of a fetus 
with a deletion in the DMD gene. (A) Schematic representation of the 
primers used for cDNA synthesis and PCR. The DMD gene exons are 
indicated by numbers. The arrows below the bars indicate the posi- 
tions of antisense primers used for cDNA synthesis and PCR. The 
arrows above the bars indicate the position of the sense primer used 
for PCR. The small open bar designated P indicates the position of 
the probe used in the Southern blot analysis. (B) Southern blot anal- 
ysis of the PCR products. DNA synthesis and PCR were performed 
on RNA samples (15 pg) from normal AF cells (AF 5, 12) and AF 
cells from a fetus harboring a large deletion in the DMD gene (exons 
7-34; AF* la and AF* 1 b). The following combination of primers were 
used: cDNA, primer A, PCR, primers B and D; cDNA, primer C; 
PCR, primers C and D. The PCR products were analysed by the 
Southern blot technique using olignucleotide probe P. 
significant amounts by Western blot analysis and the 
detection of the mRNA by RNase protection analysis 
were not surprising. However, the application of this 
finding for prenatal diagnosis is rather limited. As the 
promoter of Dp71 is located just 150 kb from the 3’ end 
of the huge DMD gene and it is transcribed from only 
6% of the gene, only a small fraction of the mutations 
in the DMD gene are expected to affect the expression 
of Dp7 1. Thus while the lack of normal Dp7 1 can be 
used as a clear indication for a defect in the DMD gene, 
the presence of Dp71 does not necessarily indicate a 
normal genotype. 
One unexplained observation is the great variability 
in the amounts of dystrophin protein mRNA in differ- 
ent AF cell samples. This variability is greater in the 
cultured CVS cells. In addition, while in most samples 
only muscle-type dystrophin mRNA was identified, in 
some samples both muscle- and brain-type dystrophin 
mRNAs were detected. The biological nature of this 
variability is still unknown. It might reflect differences 
in the genetic milieu between the donor embryos; differ- 
ences in the composition of the cell population in AF 
or CVS samples which are intrinsic to the donors’ AF 
or CVS cell population; or a population drift caused by 
the amplification of small samples of cells. Compatible 
with the latter possibility is the observation that cloned 
cells derived from the same AF samples were qualita- 
tively and quantititively similar in their expression of 
dystrophin isoforms, while clones of two different do- 
nors differed in dystrophin isoform expression. Differ- 
ences in expression might also result from differences in 
the history of the cell cultures; e.g. we have noticed a 
decrease in the amounts of muscle dystrophin mRNA 
after several cell passages in one of the cloned popula- 
tions of AF cells. The understanding of this variability 
in expression will be important for the application of the 
present observations for prenatal diagnosis of DMD. 
The detection of the dystrophin protein and the Solving this problem will enable the development of 
muscle-type dystrophin mRNA in AF and CVS cells is two independent and complementary methods, based 
of special biological interest and may facilitate the de- 
velopment of a prenatal diagnosis procedure. Previous 
PCR analysis of cloned cell populations indicated that 
the expression of the dystrophin mRNAs is very strin- 
gently controlled. The muscle-type isoform is expressed 
in multinucleated muscle fibers and in glia cells, but is 
undetectable in mononucleated myoblasts before cell 
fusion or in neurons. The brain-type dystrophin mRNA 
is present in neuronal cultures but is undetectable in 
myogenic cells [38]. Here we show that the muscle-type 
dystrophin mRNA is present in low levels in AF and 
CVS cells. In some samples the brain-type dystrophin 
mRNA is also detectable. 
The identification of the protein comigrating with 
dystrophin as a genuine product of the DMD gene was 
established using two dystrophin-specific mAb’s, raised 
against different epitopes in the C-terminal domain of 
dystrophin for the immunoprecipitation step, and a 3rd 
mAb raised against an epitope in the spectrin like re- 
peats for staining the blotted protein. The identification 
of the mRNA was done using several sets of specific 
primers and different probes for the amplification and 
detection of the amplified products in the PCR analysis. 
RT/PCR analysis of an RNA sample from AF cells 
taken from an embryo with a deletion in the DMD gene 
confirmed that dystrophin is expressed in fetal cells and 
is not of maternal origin. PCR analysis also demon- 
strated that, in AF cultures containing dystrophin, ap- 
parently all clonable cells expressed ystrophin mRNA, 
and those cells were of fetal origin. 
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A. 25 cycles 
Fig. 5. Quantitative PCR analysis of muscle-type dystrophin mRNA 
in AF cells. cDNA synthesis and PCR used 15 pg of total RNA from 
the indicated tissues and cell cultures; primer 6 was used for cDNA 
synthesis and primers 7 and 8M for the PCR. An internal oligonucle- 
otide probe was used in the Southern analysis. (A) 25 cycles of PCR; 
(B) 35 cycles of PCR. Blots A and B were exposed overnight and for 
3.5 h, respectively. Mus., rat skeletal muscle cDNA. 1:lO and 1:lOO 
indicate the fold of dilution of this cDNA. 
on the expression of the gene, for prenatal diagnosis of 
DMD. (1) The detection of dystrophin in AF or CVS 
cell extracts by immuno-precipitation or other enrich- 
ment procedures followed by Western blot analysis. 
Using a panel of mAb’s raised against epitopes in the 
relevant domains of dystrophin, this method could 
provide information on the integrity of the protein. (2) 
Examination of the transcripts of the DMD gene in AF 
or CVS cells by a combination of PCR and in vitro 
transcription and translation of the PCR products. 
Since it is impossible to amplify the entire 14 kb mRNA 
in one piece, a series of primers for RT/PCR reactions 
which amplify partially overlapping nested regions cov- 
ering the entire coding sequence of dystrophin mRNA 
can be synthesized. The 5’ primer of each pair will in- 
clude a sequence for the T7 or SP6 RNA polymerase 
and an in-frame translation initiation sequence. The 
PCR products containing the polymerase initiation sites 
can then be subjected to in vitro transcription and trans- 
lation. The translation products can be analyzed on a 
gel to check whether all expected peptides are present. 
It may be possible to combine all PCR products into 
one sample which will then be separated on isoelectric 
focussing (IEF)-SDS 2D gels which will be screened 
automatically against a reference of a 2D gel of the 
products of normal CVS or AF mRNA. The feasibility 
of direct transcription and transplantation of PCR 
products has been demonstrated [39]. 
Diagnosis based on the expression of the gene has the 
advantage that it is not dependent on availability of 
informative genetic or cytological data from previous 
cases in the family. It can also potentially be applied to 
the detection of new mutations in the DMD gene, which 
comprise about 30% of all cases. 
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